Compounded Ketamine vs. Brand-Name Spravato: Full Comparison

The Two Paths to Ketamine-Based Psychiatric Treatment

Patients with treatment-resistant depression today have two clinically recognized ketamine-based options: compounded racemic ketamine (primarily IV infusions, IM injections, and sublingual troches) and brand-name Spravato (esketamine nasal spray). These are not interchangeable products — they differ in molecular identity, regulatory status, evidence base, access requirements, and cost. Understanding these differences is essential for informed treatment decisions. For a broader cost picture, see our cost comparison across all ketamine formats.

Molecular Difference: Racemic vs. S-Ketamine

This is the starting point for all other differences.

Compounded ketamine contains racemic ketamine — a 50/50 mixture of two enantiomers (mirror-image molecules):

• R-ketamine: Less potent at NMDA receptors; may have antidepressant effects through mechanisms independent of NMDA blockade, including AMPA receptor modulation and mTOR pathway activation
• S-ketamine: More potent at NMDA receptors; faster onset, greater dissociation per milligram

Spravato (esketamine) contains only the S-enantiomer. Johnson & Johnson selected S-ketamine for Spravato's development because it is more potent and predictable, and the company could obtain patents on the enantiomerically pure formulation — which is not possible for generic racemic ketamine. See our article on active ingredients for more on the racemic ketamine used in troches.

Some researchers, including Kenji Hashimoto's laboratory, have argued that R-ketamine may have longer-lasting and more sustained antidepressant effects than S-ketamine, with less abuse potential. This remains an active area of research. The clinical implications for patients choosing between racemic compounded ketamine and Spravato are not fully resolved.

FDA Approval Status

Spravato

• FDA-approved in 2019 for treatment-resistant depression (TRD) in adults
• FDA-approved in 2020 for MDD with acute suicidal ideation or behavior (MDD-SI)
• Approved in conjunction with an oral antidepressant — not as monotherapy
• Subject to REMS (Risk Evaluation and Mitigation Strategy) requiring certified healthcare settings for administration
• Post-market surveillance data continues to accumulate

Compounded Ketamine

• Not FDA-approved as a psychiatric drug product
• Legal under 503A compounding for individual prescriptions
• Ketamine itself has been FDA-approved since 1970 as an anesthetic; psychiatric use is off-label
• No REMS requirement; no mandatory treatment setting restrictions for troches (though prescribers impose their own protocols)

FDA approval matters for insurance coverage, regulatory certainty, and the assurance that the product has met safety and efficacy standards in controlled trials. It does not guarantee superior efficacy compared to off-label alternatives.

Evidence Base

Spravato Clinical Trials

Spravato's approval was based on multiple Phase 2 and Phase 3 randomized controlled trials including:

• TRANSFORM-1, -2, and -3 (esketamine for TRD)
• ASPIRE-1 and -2 (esketamine for MDD-SI)

These trials demonstrated statistically significant improvement on the MADRS (Montgomery-Åsberg Depression Rating Scale) compared to placebo. The TRANSFORM-2 trial is the pivotal study for TRD approval.

Important caveat: Several Spravato trials had mixed results, and the effect sizes in some studies were modest. The FDA advisory committee review was not unanimous.

Compounded Racemic Ketamine

IV racemic ketamine has been studied in dozens of trials over two decades. Meta-analyses consistently show rapid, robust antidepressant effects — effect sizes comparable to or exceeding those seen in Spravato trials. The Murrough et al. (2013) trial and Zarate et al. (2006) studies are landmark references.

Sublingual/troche-specific data is less extensive but growing, with observational studies and some controlled work supporting efficacy for TRD in outpatient settings.

Critically, no head-to-head randomized trial directly comparing IV racemic ketamine to Spravato has been published. Indirect comparisons through network meta-analyses suggest racemic ketamine may be more effective, but this conclusion requires cautious interpretation.

Cost Comparison

Spravato

Spravato is extraordinarily expensive at list price:

• 56 mg dose (2 devices): ~$590 per session
• 84 mg dose (3 devices): ~$885 per session
• Acute phase (twice weekly for 4 weeks): Up to ~$7,000 at list price
• Maintenance phase (once or twice monthly): $1,000 to $2,000 per month

With commercial insurance coverage, costs may be dramatically reduced (copay assistance programs can reduce costs to near zero for some patients). Without insurance, Spravato is prohibitively expensive for most patients.

Compounded Ketamine (Troches)

Monthly troche therapy costs approximately $150 to $400 in medication plus $100 to $300 in provider fees — totaling $250 to $700 per month, with or without insurance (as insurance rarely covers compounded products).

IV ketamine clinic sessions cost $400 to $800 each, making a 6-session acute course $2,400 to $4,800.

For patients without insurance coverage for Spravato, compounded ketamine is dramatically more affordable.

Administration and Access

Spravato

• Must be administered in a certified healthcare facility (REMS requirement)
• Patient self-administers the nasal spray at the facility
• Minimum 2-hour monitoring period after each dose at the facility
• Requires a certified provider and a certified treatment center
• Not available in all geographic areas (depends on certified facility locations)
• Patient cannot drive on treatment days

Compounded Ketamine Troches

• Prescribed by any licensed provider authorized to prescribe controlled substances
• Administered at home by the patient
• No mandatory monitoring period at a facility
• Accessible wherever a telehealth prescriber can practice and a compounding pharmacy can ship
• No facility certification requirement

For patients in rural areas or those with transportation limitations, compounded troches may be the only practically accessible ketamine-based option.

Insurance Coverage

Spravato

Spravato can be covered by insurance for approved indications with prior authorization. Commercial insurers, Medicare, and Medicaid may cover Spravato. Coverage criteria typically include documented prior treatment failures (typically 2 or more antidepressants).

Coverage decisions are not guaranteed — prior authorization can be denied, and coverage policies vary by insurer. Patients should check with their insurer before starting a Spravato program.

Compounded Ketamine

Insurance almost never covers compounded ketamine troches. As a non-FDA-approved compounded product, it is typically classified as an experimental or cosmetic treatment by insurers. FSA and HSA funds may be usable for compounded ketamine expenses with appropriate documentation.

Patient Experience Differences

Spravato Experience

• Nasal administration: Some patients experience nasal discomfort, drip, or irritation
• 2-hour facility stay is required but also provides a structured, monitored environment
• Some patients experience the monitored setting as reassuring

Troche Experience

• Oral administration: Some experience bitterness and the prolonged dissolution process
• Home environment allows personalized set and setting
• Longer duration (2 to 3 hours) compared to esketamine sessions (1 to 2 hours)

Making the Choice

Many patients end up making this choice based primarily on insurance coverage. If Spravato is covered and accessible, it's a reasonable first choice for TRD with strong evidence backing. If not, compounded ketamine (especially IV or troches) provides clinically effective options with a longer track record in clinical practice.

Key Takeaways

• Spravato uses only S-ketamine; compounded options use racemic ketamine (both enantiomers).
• Spravato is FDA-approved for TRD and MDD-SI; compounded ketamine is legal off-label prescribing.
• Spravato requires in-facility administration with 2-hour monitoring; troches can be used at home.
• Spravato may be covered by insurance; compounded troches typically are not.
• At list price, Spravato is far more expensive than troches; with insurance, the patient cost may be lower.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches